About Anacalypsis Therapeutics
Anacalypsis Therapeutics is a Greece-based biotechnology company developing new therapeutic approaches for Parkinson’s disease and related neurodegenerative disorders. Its lead program, AT001, targets the interaction between the LRRK2 and FADD proteins. The company is also developing additional therapeutic programs and biomarker technology to support patient selection and disease monitoring.
News and Update
Metavallon VC Invests in Anacalypsis Therapeutics through the Brain Gain Fund – A Pre-Seed Financing Round to Advance Potential New Parkinson’s Disease Treatment. For more information
https://www.anacalypsistherapeutics.com/
